Implementation & Service Delivery
A psychedelic therapy that works in a trial still has to be delivered in the real world, to many people, affordably, safely and well, and that turns out to be one of the hardest unsolved problems in the field. This page is about the mechanics: who delivers the therapy, how they are trained, whether sessions are one-to-one or in groups, how it fits into a health system, and what it costs. The honest picture is of a field still improvising. Real-world data are thin, dominated by ketamine clinics and a handful of feasibility pilots; the psychological-support component is essential but contested and hard to standardise; the trained workforce needed is enormous and does not yet exist; and the most-discussed solution, group delivery, promises big savings on paper while remaining unproven in practice. The science of whether these therapies work is racing ahead of the much harder question of how to actually provide them.
Data updated
Key Insights
- 1
This is a delivery and implementation page, not a condition or a treatment. It asks how psychedelic-assisted therapy is actually provided in the real world: the service models, the workforce, the settings, the costs, and how it fits into health systems.
- 2
Real-world delivery data are thin and uneven. Ketamine is the only psychedelic with genuine real-world clinic data; psilocybin and MDMA delivery exists in a few regulated programmes (Oregon, Australia, emerging NHS models) but with almost no published outcome or throughput data yet.
- 3
The therapy component is both essential and unsettled. Most people using psychedelics want psychological support, far more than receive it, yet there is genuine debate about how much support is needed, who should provide it, and how to standardise something so sensitive to context.
- 4
The workforce is the binding constraint. Delivering one-to-one psychedelic therapy at population scale would require a trained workforce that does not exist, which is why group delivery is the most-discussed solution, promising large cost savings on paper while remaining at the feasibility stage.
- 5
Cost and equity are unresolved. The gap between a $5 dose of generic ketamine and a $600-900 branded one, and between expensive private therapy and equitable public access, shows that affordability of the drug is the easy part; the labour-intensive therapy around it is what makes scale and fairness hard.
By the numbers
- 29
- Trials tracked
- 31
- Papers tracked
- 2,344
- Trial participants
as of July 2026
as of July 2026
as of July 2026
Research Landscape
What the 29 registered trials connected to Implementation & Service Delivery look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
How fast is Implementation & Service Delivery research growing?
SourcedRegistered trials by recorded study-start year. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (29 of 29 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
What's live right now, and what stopped?
SourcedRegistry status of all 29 Implementation & Service Delivery trials Blossom tracks. Orange marks trials recruiting or opening.
- Recruiting or opening
- 1241%
- Underway, not recruiting
- 13%
- Completed
- 931%
- Stopped early
- 27%
- Unknown / other
- 517%
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Which compounds carry the Implementation & Service Delivery research?
SourcedTrials per compound. Orange marks the most-studied compound.
Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.
About Implementation & Service Delivery
Implementation and service delivery is not a condition or a treatment; it is the unglamorous, decisive question of how a psychedelic therapy actually reaches people once the trials are done. A successful trial answers "does this work in a controlled setting?". This page is about everything that comes after: who provides the therapy, how they are trained and supervised, whether people are treated one at a time or in groups, what kind of clinic or service is needed, how it slots into a health system, and what the whole thing costs. These are not afterthoughts. They determine whether a promising treatment becomes a real option for ordinary patients or stays a boutique intervention for the few.
This is also one of the field’s most genuinely unsolved areas, and an honest page has to treat it as emerging rather than established. The evidence here is not efficacy trials but implementation studies, service-model proposals, workforce analyses, cost projections and a small number of real-world programmes. Much of it is description and argument about how delivery might work, with relatively little hard data on how it actually does. The field is, in effect, building the aeroplane while flying it.
The single most important idea to carry through this page is that the drug is the easy part and the therapy is the hard part. A dose of psilocybin or ketamine is cheap and simple; the hours of skilled human preparation, support and integration around it are expensive, labour-intensive and difficult to standardise. That is why delivery is so much harder than efficacy, and why the questions on this page, about workforce, cost, fidelity and access, are inseparable from the questions of health economics and public health covered elsewhere. How to provide this well, to many, affordably, is the bottleneck the whole field now faces.
Approach & Methods
Because there is no condition here, the relevant "current practice" is the small and uneven set of real-world delivery models. The clearest reality is that ketamine, not the classic psychedelics, is what is actually being delivered at scale: it has the only genuine real-world clinical dataset on the page, an academic-clinic programme treating a comorbid, messy real-world population quite unlike a trial sample[1]. The classic psychedelics exist in delivery only in a few regulated settings, Oregon’s licensed psilocybin services, Australia’s authorised-prescriber access to psilocybin and MDMA, and emerging models such as a proposed NHS pathway for psilocybin[2], but with almost no published outcome or throughput data.
What the real-world picture mostly reveals is a large gap between how psychedelics are used and how clinical care imagines them. Surveys find that most use happens far outside the clinic: the great majority of users never discuss it with their doctor, and only a tiny fraction use in a clinical setting[3], even as the public broadly supports supervised, licensed provision[4]. So the "standard" of delivery is really two disconnected worlds, a small, intensive clinical model and a large, unsupervised naturalistic one, and much of implementation science is about how, or whether, to bridge them, including by using pragmatic trials and real-world data rather than relying on confirmatory trials alone[5].
This report summarises what Blossom’s database shows about the implementation and service delivery of psychedelic therapies, how, in practice, they get from a trial to a patient. It is worth being clear what kind of page this is. It is not a condition page and not a treatment. It is about the operational reality of delivery, and it is one of the most emerging, least settled topics in the field: rich in proposals and projections, thin in hard real-world data.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics or to seek out any particular service. It is also a page about logistics rather than efficacy: it does not assess whether these therapies work, which is covered on the condition pages, but how they might be delivered. Read it as an honest account of an unsolved practical problem, not as a guide to treatment.
Why delivery is the real bottleneck
It is easy to assume that once a therapy is proven, providing it is a matter of detail. For psychedelic therapy, the opposite is true: delivery may be the harder problem. The drug itself is cheap and simple to administer. What surrounds it, careful screening, hours of preparation, a long supervised dosing session, and structured integration afterwards, is expensive, time-intensive and skilled. A single course can consume many hours of trained clinicians’ time. Multiply that by the millions of people with the conditions these therapies target, and the scale problem becomes obvious. This is why implementation, not efficacy, is increasingly seen as the field’s rate-limiting step.
The evidence base reflects how new this all is. There is essentially no controlled data on delivery; instead there are service-model proposals, feasibility pilots, workforce analyses, cost projections and a few real-world cohorts. The only genuine real-world clinical dataset of any size here is a retrospective review of a real-world ketamine programme for treatment-resistant depression, in a population far more comorbid and complicated than any trial sample[1]. That single, uncontrolled, 41-patient study being the strongest real-world outcome dataset tells you how early the field is.
The therapy component: essential, contested, hard to standardise
At the heart of delivery sits an unresolved question: how much of psychedelic therapy is the drug, and how much is the human support around it? Everyone agrees the psychological component matters, but there is real debate about how much is needed, who should provide it, and how to standardise something so dependent on relationship and context. The demand is not in doubt. Surveys of people using psychedelics find a striking gap: the large majority want therapeutic support during their experiences, while only a small minority actually receive it[2]. People want the human element; the system cannot yet supply it.
This is genuinely hard to operationalise. A drug dose can be standardised; a supportive, attuned therapeutic presence cannot, easily. The field has begun to grapple with this, including through proposals to use pragmatic, real-world research to discover what delivery protocols actually work best[3], but it remains one of the least-settled parts of implementation. How do you train for it, supervise it, measure whether it was done well, and reproduce it across hundreds of clinics? Those questions, about fidelity and quality, are barely answered in the current evidence, and that gap is itself an honest finding.
The workforce problem, and the group-therapy answer
If delivery is labour-intensive and the therapy component is essential, the binding constraint becomes people: there are nowhere near enough trained facilitators to deliver one-to-one psychedelic therapy at population scale, and training them is slow and contested. The field’s own ethics consensus singled out training, education and licensure as core unresolved issues[4]. The most-discussed solution is to treat people in groups rather than individually. A prominent cost analysis estimated that group delivery could save around half the clinician cost for MDMA therapy and a third for psilocybin, and free up thousands of clinician-years[5], and feasibility programmes such as a group psilocybin model for cancer patients[6] are testing whether it can be done well.
But the group solution should be read with care. Those cost savings are models, not realised results, and group delivery trades away individual attention for throughput. Whether the benefit seen in one-to-one trials survives in a group of strangers, whether vulnerable people are adequately supported in that setting, and whether it is safe as well as efficient, are open questions that feasibility pilots have only begun to address. Group therapy is the most plausible answer to the scale problem; it is not yet a proven one.
Cost, access and the two-tier risk
The economics of delivery expose an uncomfortable truth: the drug is affordable and the care is not. Ketamine makes the point vividly. As a generic it costs a few dollars a dose, yet a branded version costs hundreds, and even the cheap generic has not become accessible, with public subsidy requests repeatedly rejected[7]. The expensive part is rarely the molecule; it is the hours of skilled human time around it. That is why proposals for system integration, such as a model for delivering psilocybin within the NHS, stress that it must be available not only to those who can pay but to all on an equitable basis[8] precisely because the default, without deliberate effort, is the opposite.
The clearest risk in the whole topic is a two-tier reality. A great deal of current psychedelic use already happens outside any clinical system: the great majority of users never discuss it with their doctor, and only a tiny fraction use in clinical care[9], a pattern echoed in large national surveys of naturalistic use[10]. If formal services emerge as expensive, boutique offerings, the result could be polished private care for the affluent alongside unsupervised self-treatment for everyone else. The lessons from early attempts to move these therapies into ordinary community clinics, which surfaced challenges from infrastructure to clinical practice to public perception[11], show how much deliberate design it will take to avoid that outcome.
Reading this honestly
So how should you read the implementation story? As the field’s most important and least-finished work. The science of whether psychedelic therapies work has advanced dramatically; the science of how to actually deliver them, to many people, affordably, safely, equitably and well, has barely started. The real-world evidence is thin and dominated by ketamine clinics and small feasibility pilots; the psychological-support component that may be essential is also the hardest thing to standardise; the trained workforce required does not exist, and the leading solution, group delivery, is promising but unproven and trades intimacy for throughput; and the costs that matter are not the drug but the human care around it, which makes equitable access a real and unsolved challenge. The most useful thing this literature offers an honest reader is a corrective to the assumption that approval is the finish line. It is closer to the starting line of a second, harder race, and the field is, candidly, still working out how to run it. A therapy that cannot be delivered well and fairly to the people who need it is not yet, in the way that matters most, a treatment.
Free Account Narrative Report
Create a free Blossom account to read this narrative synthesis.
Research Outlook
The defining problem for the field’s future is the workforce, and the most-discussed answer is group delivery. The arithmetic is stark: providing one-to-one psychedelic therapy to everyone who might benefit would require a trained workforce far larger than exists. A widely cited cost model found that group delivery could save roughly half the clinician cost for MDMA-assisted therapy and a third for psilocybin, freeing thousands of clinician-years[1]. Early group programmes, such as the HOPE psilocybin-group model for cancer patients[2], are testing whether this is feasible in practice.
The honest caveat is that these savings are projections, and group delivery trades something real, individual attention and intimacy, for throughput, with little outcome data yet on whether benefit survives the trade. The deeper unsolved questions are about the human element: how to train and supervise enough facilitators (a priority flagged even in the field’s ethics consensus, which named training and licensure as core[3]), and how to standardise a psychological support process that is, by its nature, hard to pin down. The outlook is a field that knows its scalability problem intimately and has plausible but unproven solutions, with the workforce bottleneck, not the drug, as the rate-limiting step.
Industrial Landscape
The implementation question pulls in an unusually practical mix of players: health systems and regulators designing the rules (Oregon, Australia’s TGA, the NHS), the clinics and training organisations building the delivery infrastructure, and the cost-bearers, insurers and governments, deciding what gets funded. The lessons emerging from the front line are sobering. Translating these therapies into ordinary community clinics has surfaced whole categories of challenge, from inadequate infrastructure to poor clinical practice, prompting calls for multidisciplinary oversight[1], and even where a drug is cheap, access can stall: the affordability of generic ketamine has not translated into accessibility, with subsidy requests repeatedly rejected[2].
For an honest broker, implementation is where the field’s optimism meets its hardest practical limits, and the responsible posture is to take those limits seriously. The science of efficacy is advancing fast; the science of delivery is barely begun, resting on a handful of real-world cohorts, feasibility pilots, cost projections and service-model proposals rather than robust outcome data. The genuine risk is a two-tier reality, in which these therapies are delivered well to those who can pay and patchily, or not at all, to everyone else. The most useful framing keeps a clear distinction between "this works in a trial" and "we know how to provide this, at scale, affordably and equitably", credits the serious work on group models, training and real-world data, and is candid that the central problems, the workforce, the cost of the human therapy, the fidelity of delivery and the fairness of access, remain unsolved.
Blossom Pro Structured Analysis
Unlock compound evidence, clinical outlook, and stakeholder analysis.
Quick Indicators
Organisations
Search →National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation headquartered in Madison, Wisconsin. Usona develops and supports clinical research on psilocybin and other consciousness-expanding medicines with a mission-driven access model. Its psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study, Usona launched the Phase 3 uAspire trial in 2024, a 240-participant randomised, double-blind multicentre study of 25 mg psilocybin with psychosocial support for adults with MDD. In April 2026, industry reporting said Usona confirmed it had received an FDA Commissioner National Priority Voucher for psilocybin in MDD, potentially shortening review if an NDA is filed and accepted. Usona is also exploring 5-MeO-DMT in early-stage research.
University of California San Diego
The Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
University College London
The Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.
Canadian Forces Health Services Centre Ottawa
The Canadian Forces Health Services Centre Ottawa is the primary military healthcare facility serving the National Capital Region, providing comprehensive medical, mental health, and occupational health care to Canadian Armed Forces (CAF) personnel and their families. The centre supports CAF members with psychiatric services relevant to trauma and PTSD, areas in which the Canadian military has shown growing interest in ketamine-based and psychedelic-assisted therapies as emerging treatment options.
Centre for Neurology Studies, Canada
The Centre for Neurology Studies (CNS) is a private clinical research centre in Surrey, British Columbia, and one of Canada’s few dedicated neuroscience-focused clinical trial organizations, conducting Health Canada and FDA-approved studies in mental health, neurodegenerative disorders, and brain health. Operating within British Columbia’s growing clinical trials ecosystem, CNS has participated in research on novel psychiatric treatments relevant to the emerging psychedelic medicine field.
Denver Health and Hospital Authority
Denver Health and Hospital Authority is a public integrated healthcare system serving the Denver metropolitan area as the city's primary safety-net provider for uninsured and underinsured populations. Its Rocky Mountain Poison and Drug Safety division has contributed to psychedelic research policy in Colorado, including peer-reviewed guidance on post-market safety data collection following the state's legalisation of psilocybin under Proposition 122.
Empower Psychedelics
Empower Psychedelics is a Canada-based non-profit conducting Health Canada-approved psychedelic-assisted group therapy research for first responders and military veterans in partnership with MAPS Canada. Founded in 2020 by former first responders, the organization received a $205K Mitacs grant with the University of Quebec in Montreal for a two-year clinical research program.
People
Search →Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
Michael Ashton
Professor of Clinical Pharmacology at the University of Gothenburg
He is a pharmacometrics and clinical pharmacology researcher whose work has been used in psychedelic studies on DMT pharmacokinetics, pharmacodynamics, EEG effects, and psychedelic intensity modeling.
John Smallridge
Researcher at Reconnect Labs AG
He is a coauthor on several recent psychedelic pharmacology and consciousness studies involving DMT, harmine, psilocybin, and EEG/TMS-EEG methods.
David Feifel
Professor Emeritus of Psychiatry at the University of California, San Diego; President of Kadima Neuropsychiatry Institute
David Feifel is a prominent psychiatrist and neuropsychiatrist who helped pioneer ketamine-based treatment programs and has coauthored clinical psychedelic research on psilocybin for treatment-resistant depression.
Michael Mithoefer
Senior Medical Director for Medical Affairs at MAPS PBC
Conducted the first FDA-approved clinical trial of MDMA-assisted therapy for PTSD.
Mark Wagner
Professor of Neurology at the Medical University of South Carolina
Mark Wagner is a notable figure in the field of psychedelic research, particularly focusing on the therapeutic implications of personality changes following trauma.
Handersson Barros
Psychologist and psychotherapist
He is a named coauthor on early clinical DMT studies, including safety and antidepressant-effect trials, indicating direct involvement in psychedelic clinical research.
Alan Davis
Associate Professor of Social Work & Director, Center for Psychedelic Drug Research
Noted for advancing epidemiological, naturalistic and mixed-method research on therapeutic and adverse outcomes of psychedelics and for translating those findings into clinical and harm-reduction contexts.
Frederick Barrett
Senior Research Scientist
Frederick S. Barrett is a leading researcher in contemporary psychedelic science noted for developing psychometric tools, characterising challenging and insightful psychedelic experiences, and contributing to neuroimaging and safety research on psilocybin and other classic psychedelics.
Connected Evidence
The latest clinical data and verified academic findings associated with Implementation & Service Delivery.